Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet

BACKGROUND: After receiving entecavir or combined with FuzhengHuayu tablet (FZHY) treatment, some sufferers with hepatitis B virus (HBV)-related liver fibrosis could achieve a histological improvement while the others may fail to improve even worsen. Serum metabolomics at baseline in these patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Yun-Kai, Fan, Hai-Na, Huang, Kai, Sun, Xin, Zhao, Zhi-Min, Liu, Cheng-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600694/
https://www.ncbi.nlm.nih.gov/pubmed/37900214
http://dx.doi.org/10.4254/wjh.v15.i9.1043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600694/
https://www.ncbi.nlm.nih.gov/pubmed/37900214
http://dx.doi.org/10.4254/wjh.v15.i9.1043

Ejemplares similares